Damora Therapeutics (DMRA) Assets (2019 - 2026)
Damora Therapeutics' (DMRA) quarterly Assets came in at $535.4 million in Q1 2026, up 3384.82% YoY from $15.4 million in Q1 2025, and up 105.52% on a QoQ basis from $260.5 million in Q4 2025.
Damora Therapeutics (DMRA) Assets (2019 - 2026) Analysis & Trends
Damora Therapeutics (DMRA) has 8 years of Assets data on file, last reported at $535.4 million in Q1 2026.
- Quarterly Assets rose 3384.82% year-over-year to $535.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $535.4 million (up 3384.82% YoY) and the FY2025 annual result came in at $260.5 million, up 1420.7% from the prior year.
- Assets grew to $535.4 million in Q1 2026, from $260.5 million in the prior quarter.
- In the past five years, Assets ranged from a high of $535.4 million in Q1 2026 to a low of $10.7 million in Q3 2025.
- A 5-year average of $88.5 million and a median of $50.0 million in 2023 frame the typical range for Assets.
- Annual changes were most pronounced in 2024 — Assets sank 55.18% — and 2026, when it soared 3384.82%.
- Tracing DMRA's Assets over 5 years: stood at $73.2 million in 2022, then sank by 47.77% to $38.2 million in 2023, then slumped by 55.18% to $17.1 million in 2024, then jumped by 1420.7% to $260.5 million in 2025, then jumped by 105.52% to $535.4 million in 2026.
- The last three Assets figures came in at $535.4 million (Q1 2026), $260.5 million (Q4 2025), and $10.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - | 543.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 543.64 Mn |
| Mar 31, 2026 | 535.44 Mn |
| Dec 31, 2025 | 260.53 Mn |
| Sep 30, 2025 | 10.74 Mn |
| Jun 30, 2025 | 13.69 Mn |
| Mar 31, 2025 | 15.37 Mn |
| Dec 31, 2024 | 17.13 Mn |
| Sep 30, 2024 | 23.38 Mn |
| Jun 30, 2024 | 27.30 Mn |
| Mar 31, 2024 | 32.48 Mn |
| Dec 31, 2023 | 38.23 Mn |
| Sep 30, 2023 | 50.05 Mn |
| Jun 30, 2023 | 58.80 Mn |
| Mar 31, 2023 | 64.63 Mn |
| Dec 31, 2022 | 73.19 Mn |
| Sep 30, 2022 | 82.03 Mn |
| Jun 30, 2022 | 92.86 Mn |
| Mar 31, 2022 | 108.93 Mn |
| Dec 31, 2021 | 122.22 Mn |
| Sep 30, 2021 | 135.87 Mn |